Addex Therapeutics vs InflaRx
ADXN and IFRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADXN and IFRX compare
InflaRx grew revenue faster over the last twelve months (−82.3% versus −92.6% for Addex Therapeutics).
InflaRx scores higher on the StockData Score (5 against 0 for Addex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADXN | IFRX |
|---|---|---|
| Size and price | ||
| Share price | $4.06 | $1.17 |
| Change, 1 year | −53.9% | −19.9% |
| Change, 5 years | −97.1% | −75.4% |
| Beta (5Y) | 0.90 | 1.47 |
| Employees | 3 | – |
| StockData Score | ||
| Total score | 0 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −92.6% | −82.3% (better) |
| Revenue growth, 5Y average | −61.6% | – |
| EPS growth (TTM) | −186% | – |
| Profitability | ||
| Gross margin | – | −24678% |
| Operating margin | −9391% | – |
| FCF margin | −7244% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −181.0× | – |
| Current ratio | 0.76 | 4.13 (better) |
| Ownership | ||
| Held by institutions | 0.00% | 135% |
| Held by insiders | 15.5% | 6.0% |
Go deeper
- ADXN stock overview
- ADXN income statement
- ADXN valuation and score
- IFRX stock overview
- IFRX income statement
- IFRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.